Pre-eclampsia and Biochemical Markers

Overview

In view of both endothelial injury in pre-eclampsia, high blood pressure and kidney impairment characteristics, a recent study demonstrated that the serum levels of NGAL increased at the end of the second trimester in women who subsequently developed pre-eclampsia compared to the control group. This correlates well with the endothelial damage that occurs during pre-eclampsia and thus NGAL can be considered as a promising marker in predicting both early and late onset pre-eclampsia. It may be required to combine one or more biomarker with NGAL to increase the precision, and sensitivity for detection of risk and reliability of using biomarkers for pre-eclampsia.

Full Title of Study: “Correlation Between Complications of Pre-eclampsia and Detection of Novel Biochemical Markers”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2016

Arms, Groups and Cohorts

  • Eclampsia
    • pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
  • severe preeclampsia
    • pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
  • healthy
    • matched normotensive pregnant women.

Clinical Trial Outcome Measures

Primary Measures

  • The level of circulating NGAL
    • Time Frame: 24 hours

Participating in This Clinical Trial

Inclusion Criteria

  • Age 20-40 years. – Gestational age >20 weeks. Exclusion Criteria:

  • Patients with preexisting renal disease,hypertension, diabetes mellitus, gestational hypertension. – Patients Refuse to participate in the study – Patients already have complicated preeclampsia.

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ahmed Mohamed Abbas, Lecturer – Assiut University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.